Skip to main content
CRDF
NASDAQ Life Sciences

Cardiff Oncology Q3: Cash Falls to $33.8M, Going Concern Reiterated as Phase 3 Looms

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.728
Mkt Cap
$56.604M
52W Low
$0.72
52W High
$3.31
52W Position info
1.0% above low
Off High info
78% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

CRDF is trading near its 52-week low of $0.72 (1.0% above the low).

Summary

Cardiff's Q3 10-Q shows $33.8 million in cash and investments — enough to fund operations only to the end of Q3 2027 — with management repeating substantial doubt about going concern ahead of a Phase 3 mCRC trial.


Key Events · Earnings and Guidance · CRDF

  • Going Concern Doubt Reiterated

    Management concluded there is substantial doubt about the company's ability to continue as a going concern; $33.8 million in cash, cash equivalents and short-term investments is not sufficient to meet funding requirements for at least the next 12 months.

  • Cash Burn Leaves Runway to Q3 2027

    Cash and investments fell to $33.8 million at September 30, 2026 from $58.3 million at December 31, 2025, with $33.9 million of operating cash used in the nine months.

  • Loss Narrows on Lower R&D

    Nine-month net loss was $30.4 million versus $38.6 million a year earlier; R&D fell to $17.7 million from $30.3 million as trials completed, while SG&A rose to $14.3 million from $11.2 million on NMS litigation costs.

  • July Offering Adds $9.1M Net

    The July 2026 registered direct sold 9,293,079 shares with warrants at $1.05 ($1.455 for insiders) for $10.05 million gross and $9.1 million net; 9,757,732 warrants at a $1.31 strike become exercisable January 19, 2027.


Analysis · CRDF · Life Sciences

Cardiff ended September with $33.8 million in cash and investments, down from $58.3 million at year-end, and management says that only funds operations to the end of Q3 2027 — not enough for the next 12 months. That is a substantial-doubt going-concern statement on a company that must fund a ~640-patient Phase 3 mCRC trial, so another raise is close to certain and dilution is the base case. The offset is that spending is coming down (R&D $17.7 million for nine months vs $30.3 million) and the net loss narrowed to $30.4 million from $38.6 million, while the July offering brought in $9.1 million net and the Nerviano dispute is settled. The stock trades near its 52-week low of $0.72, which makes the next financing expensive.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRDF was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.6M. The 52-week trading range was $0.72 to $3.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRDF - Latest Insights

CRDF
Nov 12, 2026, 4:21 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7276
Real-time Price: $0.740 info
Change: +$0.0124 (+2%) info
Market Cap: $56.604M info
CRDF
Nov 12, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7695
Real-time Price: $0.740 info
Change: -$0.0295 (-4%) info
Market Cap: $56.604M info
CRDF
Oct 27, 2026, 4:44 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8988
Real-time Price: $0.740 info
Change: -$0.1588 (-18%) info
Market Cap: $56.604M info
CRDF
Oct 21, 2026, 6:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.740 info
Change: -$0.210 (-22%) info
Market Cap: $56.604M info
CRDF
Sep 14, 2026, 9:28 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.24
Real-time Price: $0.740 info
Change: -$0.4981 (-40%) info
Market Cap: $56.604M info